

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|---|----|---|--------------------------|------------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 10/578,589-Conf. #9455 |
| | | | | Filing Date | December 13, 2006 |
| | | | | First Named Inventor | Anne-Sophie Bessis |
| | | | | Art Unit | 1625 |
| | | | | Examiner Name | T. A. Solola |
| Sheet | 1 | of | 2 | Attorney Docket Number | 65517(53196) |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|-----------------------|---|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Document Number Number-Kind Code ² (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | AA | US-2003/0149049 | 08-07-2003 | Arkin et al. | |
| | AB | US-3,991,064 | 11-09-1976 | Brown et al. | |
| | | | | | |
| | | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|-----------------------|--|--------------------------------|--|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear | T ⁶ |
| | BA | WO-03/027080 | 04-03-2003 | Mitsubishi Pharma Corporation, Sanofi-Synthelabo | | |
| | BB | WO-2004/085408 | 10-07-2004 | Mitsubishi Pharma Corporation, Sanofi-Synthelabo | | |
| | BC | WO-2004/052864 | 06-24-2004 | Pfizer Products Inc. | | |
| | BD | WO-01/02375 | 01-11-2001 | AXYS Pharmaceuticals, Inc. | | |
| | BE | WO-01/54507 | 08-02-2001 | Akkadix Corporation | | |
| | BF | WO-03/037888 | 05-08-2003 | Mitsubishi Pharma Corporation, Sanofi-Synthelabo | | |
| | BG | WO-91/04250 | 04-04-1991 | Schering Aktiengesellschaft Berlin Und Bergkamen | | |
| | BH | GB-950,872 | 02-26-1964 | Boissier, et al. | | |
| | BI | WO-03/066595 | 08-14-2003 | Euro-celtique S.A. | | |
| | BJ | WO-2004/011441 | 02-05-2004 | Euro-celtique S.A. | | |
| | BK | WO-2004/014902 | 02-19-2004 | Astrazeneca AB | | |
| | BL | WO-2004/029031 | 04-08-2004 | Euro-celtique, S.A. | | |
| | BM | WO-2004/038374 | 05-06-2004 | Merck & Co., Inc. | | |
| | BN | WO-2004/058754 | 07-15-2004 | Euro-celtique S.A. | | |
| | | | | | | |
| | | | | | | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|---|----|---|--------------------------|------------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 10/578,589-Conf. #9455 |
| | | | | Filing Date | December 13, 2006 |
| | | | | First Named Inventor | Anne-Sophie Bessis |
| | | | | Art Unit | 1625 |
| | | | | Examiner Name | T. A. Solola |
| Sheet | 2 | of | 2 | Attorney Docket Number | 65517(53196) |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|--------------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | CA | Rogers, et al., Neurobiology of Aging, Vol. 17, No. 5, pp. 681-686 (1996). | |
| | CB | Yan, et al., J. Comb. Chem., Vol. 5, No. 5, pp. 547-559 (2003). | |
| | CC | Phillips, et al., J. Med. Chem., Vol. 35, No. 4, pp. 743-750 (1992). | |
| | CD | Toja, E. et al., Farmaco Sci., Vol. 39, No. 5, pp. 450-462 (1984). | |
| | CE | CAS Registry No. 695195-63-2, Chemical Library, Supplier: Chemical Block Ltd, CAS Registry (2004) | |
| | CF | Copy of Opposition filed in the name of Sanofi-Aventis in corresponding European Patent No. 1 685 105 B1. | |
| | CG | Copy of Opposition filed in the name of Dr. Thorsten Bausch in corresponding European Patent No. 1 685 105 B1. | |
| | | | |
| | | | |
| | | | |

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.